McKesson Secures $2B Credit Facility for Medical-Surgical Division

McKesson Corporation's medical-surgical division has secured $2 billion in new credit facilities through a comprehensive financing arrangement, according to an 8-K filing with the SEC on April 6, 2026. The deal provides significant liquidity and operational flexibility for the company's medical supply distribution operations through 2031.

The Deal

McKesson Medical-Surgical Top Holdings, Inc. and certain subsidiaries entered into a credit agreement on April 1, 2026, establishing three distinct facilities totaling $2 billion. The financing package includes a $750 million senior secured term loan maturing in 2031, a $250 million term loan due in 2028, and a $1 billion revolving credit facility also maturing in 2031.

JPMorgan Chase Bank serves as both administrative agent and collateral agent for the syndicated facility. The loans are secured by substantially all tangible and intangible assets of the borrower and certain material U.S. subsidiaries, providing lenders with a strong security position.

The term loans carry an initial interest rate of Adjusted Term SOFR plus 1.250% per annum, while the revolving facility features a tiered pricing structure. After June 2026, interest margins will vary based on the company's leverage ratios and credit ratings, potentially ranging from 1.250% to 1.625% over the benchmark rate. The company will also pay commitment fees between 0.175% and 0.225% on the unused portion of the revolving facility.

Strategic Rationale

This substantial credit facility strengthens McKesson's financial flexibility at a time when healthcare supply chains require significant working capital and inventory investments. The medical-surgical division, which distributes medical supplies, equipment, and pharmaceuticals to healthcare providers, operates in a capital-intensive environment requiring substantial liquidity to manage inventory cycles and customer payment terms.

The staggered maturity structure—with $250 million due in 2028 and $1.75 billion extending to 2031—provides a balanced debt profile that avoids concentration risk. The five-year tenor on the majority of the facilities suggests confidence from lenders in McKesson's long-term business stability and cash flow generation.

The secured nature of the loans, backed by division assets, likely enabled more favorable pricing terms compared to unsecured corporate debt. The variable rate structure tied to SOFR allows the company to potentially benefit if interest rates decline from current levels, though it also exposes the borrower to rate increases.

What to Watch

Investors should monitor several key aspects of this financing arrangement going forward. The credit agreement includes financial maintenance covenants requiring quarterly testing of maximum leverage ratios and minimum interest coverage ratios. These thresholds will determine both the company's compliance status and its borrowing costs, as pricing adjusts based on leverage metrics.

The $1 billion revolving facility provides significant untapped borrowing capacity for acquisitions, working capital needs, or other strategic initiatives. How McKesson deploys this liquidity will signal management's growth priorities and capital allocation strategy for the medical-surgical segment.

The customary negative covenants restrict certain activities including additional indebtedness, asset sales, and dividend payments from the subsidiary level. While standard for secured credit facilities, these limitations could impact the parent company's financial flexibility if the medical-surgical division requires support or if McKesson seeks to extract cash from this subsidiary.

Given the current interest rate environment, the all-in borrowing cost likely exceeds 5.5% based on current SOFR levels plus the 1.250% margin. This represents a meaningful interest expense that will impact divisional profitability and cash flow. Any significant changes in benchmark rates will directly affect borrowing costs and financial performance.

The involvement of JPMorgan Chase and a syndicate of lenders suggests broad institutional support for McKesson's creditworthiness. However, the secured nature of the facility, rather than unsecured corporate credit, may indicate lenders' preference for asset backing given current market conditions or sector-specific concerns.

This financing provides McKesson's medical-surgical division with substantial liquidity through the end of the decade, supporting operational needs and potential growth investments while maintaining reasonable leverage metrics.

*Source: McKesson Corporation Form 8-K filed with the Securities and Exchange Commission on April 6, 2026*

*StockCliff Research*